重大事件即時報告 8-K 2026-05-15

Anavex Life Sciences Corp. 提交 8-K 申報，披露營運總監離職

AI 繁中摘要

Anavex Life Sciences Corp. 提交 8-K 申報，披露營運總監離職 🔄

日期：2026 年 5 月 15 日（事件發生於 5 月 11 日）

申報類型：8-K（重大事件即時報告）

重點事件：
- Felix Lauscher 於 2026 年 5 月 11 日離任營運總監一職，原因是公司內部職責重組，該變動與 Terrie Kellmeyer 醫生獲任命為臨時行政總裁有關。
- Lauscher 自 2026 年 3 月 1 日起擔任該職位，任期約兩個月。

關鍵財務細節：
- 年薪：264,000 美元（按實際服務時間比例發放）
- 股票期權：獲授予 50,000 份，其中 45,833 份於離職時即時 forfeited（沒收），餘下 4,167 份已於 2026 年 3 月 31 日歸屬，可按每股 4.69 美元行使，有效期至 2026 年 8 月 9 日。
- 離職補償：提供額外兩週基本薪資，條件是簽署並不撤回一般豁免書。

對投資者的潛在影響：
- 管理層變動屬正常重組，公司已迅速任命臨時 CEO，顯示過渡平穩。
- 短期內可能引發市場對營運連續性的關注，但 Lauscher 任期極短，影響有限。
- 期權條款清晰，未見重大股權稀釋風險。

（總結：人事調整，屬於公司內部職責重新分配，投資者宜留意後續管理層穩定性。）

展開英文正文

false
 0001314052
 
 
 
 
 
 
 
 0001314052
 
 
 2026-05-11
 2026-05-11
 
 
 
 iso4217:USD
 
 
 xbrli:shares
 
 
 
 
 iso4217:USD
 
 
 xbrli:shares
 
 
 
 
 

 

 

UNITED
STATES

SECURITIES AND EXCHANGE COMMISSION

Washington,
D.C. 20549

 

FORM
8-K

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported): May
11, 2026

 

ANAVEX
LIFE SCIENCES CORP.

(Exact name of registrant as specified in its charter)

 

 
 Nevada
 001-37606
 98-0608404

 
 (State or other jurisdiction
 (Commission
 (IRS Employer

 
 of incorporation)
 File Number)
 Identification No.)

 

 

630 5th Avenue, 20th Floor, New York, NY USA
10111

(Address of principal executive offices) (Zip Code)

 

1-844-689-3939

Registrant’s telephone number, including area
code

 

Check the appropriate box below if the Form 8-K filing
is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction
A.2. below):

 

☐
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

☐
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a -12)

 

☐
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d -2(b))

 

☐
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e -4(c))

 

Securities registered pursuant to Section 12(b) of
the Act:

 

 
 Title of Each Class
  
 Trading Symbol(s)
  
 Name of Each Exchange on which Registered

 
 Common Stock, par value $0.001 per share
  
 AVXL
  
 Nasdaq Stock Market LLC

 
 

Indicate by check mark whether the registrant is an
emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities
Exchange Act of 1934 (§240.12b-2 of this chapter).

 

Emerging growth company ☐

 

If an emerging growth company, indicate by check mark
if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards
provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 

  

 

 

 

Item 5.02. Departure of Directors or Certain Officers; Election of Directors;
Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

 

Departure of Chief Operating Officer 

 

On May 11, 2026, Felix Lauscher, who had held the title
of Chief Operating Officer of Anavex Life Sciences Corp. (the “Company”) since March 1, 2026, departed from the Company as
part of a broader reorganization of duties at the Company following the appointment of Dr. Terrie Kellmeyer as the Company’s Interim
Chief Executive Officer.

 

During his tenure as Chief Operating Officer and pursuant
to his employment agreement, Mr. Lauscher had an annual base salary of $264,000, of which he received a prorated amount for his period
of service. In addition, he was granted 50,000 stock options, of which 45,833 were immediately forfeited upon his departure and 4,167
of which vested on March 31, 2026 and remain exercisable until August 9, 2026 at a price of $4.69 per share in accordance with his award
agreement and the Company’s Omnibus Incentive Plan. In connection with his departure, in consideration for the execution (and non-revocation)
of a general release he has been offered a further two weeks’ compensation at his base salary level.

 

 

  

 

 

SIGNATURES

 

Pursuant to the requirements of
the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto
duly authorized.

 

 
  
 ANAVEX LIFE SCIENCES CORP.

 
  
  

 
  
 /s/ Sandra Boenisch

 
  
 Name: Sandra Boenisch, CPA, CGA
 

 
  
 Title: Principal Financial Officer, Treasurer
 

 
  
  

 
 Date: May 15, 2026